Skip to content

Category: NIH

Watch Now: 21st Century Cures 2.0 Listening Session – Harnessing the Power of Collaboration

On July 29th, 2021, Friends of Cancer Research (Friends) hosted a virtual meeting revolving around the recently released 21st Century Cures 2.0 discussion draft. It featured a discussion panel of Representative Diana DeGette (D-CO), Representative Fred Upton (R-MI), Dr. Ned Sharpless, Director of the National Cancer Institute, and Dr. Richard Pazdur, Director of the Oncology…

How Will Expanded Eligibility Criteria Impact Clinical Trial Design?

Creating a New Cancer Research Paradigm by Broadening Eligibility Criteria The American Society of Clinical Oncology (ASCO, a professional society for cancer clinicians and researchers) and Friends of Cancer Research (Friends, a cancer advocacy organization focused on advancing science, policy, and regulation) have been collaborating to promote broader, more inclusive cancer clinical trial eligibility criteria…

Watch Now: Discussion on Eligibility Criteria and the Impact on Access to Clinical Trials

On Friday, April 9, ASCO and Friends of Cancer Research (Friends) co-hosted a live virtual event, which brought together experts from across the healthcare sector to discuss the recent release of the new ASCO-Friends recommendations for modernizing eligibility criteria to improve patient access and representation in cancer clinical trials. ASCO-Friends recommendations address five specific areas:…

22nd Annual Cancer Leadership Awards Reception

This year’s awardees at the 22nd Annual Cancer Leadership Awards Reception From L-R: Dr. Anthony Fauci, Dr. Richard Klausner September 21, 2018 The Hay-Adams 800 16th St NW, Washington, DC 20006 On September 21, 2018, Friends of Cancer Research (Friends) hosted the 22nd Annual Cancer Leadership Awards Reception. The yearly event brings together leaders in…

The FDA’s Budget: How Government Funds Safety and Efficacy

The U.S. Food and Drug Administration (FDA) fulfills its mission to protect and advance the public health by overseeing the development and approval of new medical products and ensuring that they are safe and effective for American consumers. When taking into consideration the full range of products the FDA oversees, including not just medical products,…

A Plea to Make Cancer Clinical Trials More Patient Friendly

Jim Omel is a myeloma patient and a cancer research advocate. He spoke at the 2017 Friends of Cancer Research Annual Meeting and was an author of the panel 2 whitepaper, Data Generation to Support Cross-Labeling of Indications for Combination Products. Below are his abridged remarks from the meeting. To view his remarks in full,…

Friends of Cancer Research Annual Meeting 2017

Panel 1 Whitepaper – Panel 1 Slides Panel 2 Whitepaper – Panel 2 Slides Panel 3 Whitepaper – Panel 3 Slides   This year’s Friends Annual Meeting took place on November 15, 2017. The event began with a keynote by FDA Commissioner Dr. Scott Gottlieb. During his remarks, Dr. Gottlieb reiterated previous commitments for the…

The Magic of Summer at Camp Fantastic

With summer now behind us, we thought it would be a good time to reflect on one of the special experiences our science policy analyst, Diana Merino, had over the summer… This summer, for the second year in a row, I got to spend a week volunteering at Camp Fantastic, a camp that provides an…

Keeping Patients at the Forefront of Our Work

I was 18 when my life was turned upside down by cancer. My mother was diagnosed with a highly aggressive malignancy after a colonoscopy due to a flair-up of Crohn’s disease. She spent the next two months in the hospital after the surgery to remove the malignancy left her near death with adhesions, requiring a…

Data Driven: Mining ClinicalTrials.gov – Institutions, Funding, and Areas of Focus

  This is Data Driven, a new series that explore our nation’s health agencies’ publicly available data. This data, which is comprised of searchable online databases and files, presents a unique opportunity to analyze information on broad health care topics. We thought it would be interesting to explore data from agencies whose work most closely…